Effects of Histone Methyltransferase Inhibitors on the Survival, Apoptosis and Cell Cycle of Raji Cells
Abstract
To determine the effects of three histone methylase inhibitors UNC1999, DZNep and GSK343 on the survival, apoptosis and cell cycle of non-hodgkin's lymphoma Raji cells. Methods PCR amplified 16 and 18 exons of enhancer of zeste homolog 2 (EZH2) gene were detected. The expression of EZH2 in normal adult lymphocytes and Raji cells was detected by Western blot. The Raji cells were treated by UNC1999, DZNep and GSK343, followed by CCK-8 assays analyzing cell survival, flow cytometry detecting cell apoptosis and cell cycle, and Western blot detecting the expressions of EZH2 and H3K27 me3. Results The Sanger sequencing results showed that the Raji cells did not carry Y641 and A677 mutation sites of EZH2. The Western blot results showed high expressions of EZH2 in the Raji cells. The results of CCK-8 showed that UNC1999, DZNep and GSK343 inhibited cell survival, and the weakest effect was from DZNep. The flow cytometric assay showed that UNC1999, DZNep and GSK343 promoted apoptosis of the Raji cells, and the effect of UNC1999 was stronger than that of GSK343 and DZNep. The cell cycle was arrested at phase G1/G0 after treatment of the Raji cells with the three inhibitors, with UNC1999 triggering the most significant changes. The Western blot showed that UNC1999 and GSK343 inhibited the histone methylase activity of EZH2 and significantly reduced the expression of H3K27 me3. Conclusion EZH2 inhibitors can inhibit cell survival, promote cell apoptosis and arrest cell cycle at phase G1/G0 of Raji cells through reducing the expression of H3K27me3. UNC1999 has a stronger effect than GSK343 and DZNep.
Keywords: Raji lymphoma cells, EZH2 inhibitors, Cell apoptosis, Cell cycle
Full Text:
PDFReferences
HERFARTH К. KONIG L. Radiation therapy (4 Gy vs. 24 Gy) in patients with indolent non-Hodgkins lymphoma: Results of the FORT Study. Strahlenther Onkol. 2014. 190(11): 1084-1085.
ROBERSON P. WILDERMAN S, AVRAM A. et al. Biological-effect modeling of radioimmunotherapy for non-hodgkins lymphoma: determination of model parameters. Cancer Biother Radiopharm. 2014. 29(1): 26-33.
TRNENY M, SALKOVA J. DLOUHA J. et al. Hepatic involvement in patients with non-Hodgkins lymphoma. Vnitr Lek. 2013. 59(7): 606-611.
MASUDO K. SUGANUMA N. NAKAYAMA H. et al. EZH2 Overexpression as a useful prognostic marker for aggressive behaviour in thyroid cancer. In Vivo. 2018, 32(1): 25-31.
CHEN S. YAO F. XIAO Q, et al. EZH2 inhibition sensitizes tamoxifenresistant breast cancer cells through cell cycle regulation. Mol Med Rep. 2018. 17(2): 2642-2650.
GAN L. YANG Y. LI Q, et al. Epigenetic regulation of cancer progression by EZII2: from biological insights to therapeutic potential. Biomark Res. 2018(6):10[2019-02-20).https://dx.doi.org/10.1186/s40364- 018-0122-2.
LI L. EZH2: novel therapeutic target for human cancer. Biomedicine (Taipei), 2014(4): l(2019-02-20].https://dx.doi.org/10.7603/s40681-014- 0001-6.
SNEERINGER C. SCOTT M. KUNTZ K, et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3(H3K27) in human В-cell lymphomas. Proc Natl Acad Sci U S A. 2010. 107(49): 20980-20985.
YAP D, CHU J. BERG T, et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood. 2011. 117(8): 2451-2459.
MCCABE M. GRAVES A. GANJI G. et al. Mutation of A677 in histone methyltransferase EZH2 in human В-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27(H3K27). Proc Natl Acad Sci U S A. 2012. 109(8): 2989-2994.
MORIN R. JOHNSON N. SEVERSON T. et al. Somatic mutations altering EZH2(Tyr641) in follicular and diffuse large В-cell lymphomas of germinal-center origin. Nat Genet. 2010.42(2): 181-185.
KIM K. ROBERTS C. Targeting EZH2 in cancer. Nat Med. 2016. 22(2): 128-134.
YAMAGISHI M, UCHIMARU K. Targeting EZH2 in cancer therapy. Curr Opin Oncol. 2017. 29(5): 375-381.
YAN K. LIN C. LIAO T, et al. EZH2 in cancer progression and potential application in cancer therapy: a friend or foe? Int J Mol Sci, 2017, 18(6):pii:El 172(2019-02-20). https://dx.doi.org/ 10.3390/ijms 18061172.
SIMON J. LANGE C. Roles of the EZH2 histone mcthyltransferase in cancer epigenetics. Mutat Res. 2008. 647(1/2): 21-29.
BEGUELIN W. POPOVIC R. TEATER M. et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 2013. 23(5): 677-692.
MCCABE MT, ОТТ HM. GANJI G. et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature, 2012.492(7427): 108-112.
KNUTSON SK. KAWANO S, MINOSHIMA Y, et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther. 2014. 13(4): 842-854.
BISSERIER M. WAJAPEYEE N. Mechanisms of resistance to EZH2 inhibitors in diffuse large В-cell lymphomas. Blood. 2018. 131(19): 2125-2137.
Refbacks
- There are currently no refbacks.
